- Home
- FHTX vs THRY Comparison
FHTX vs THRY Comparison
Compare FHTX & THRY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FHTX
- THRY
- Stock Information
- Founded
- FHTX 2015
- THRY 2012
- Country
- FHTX United States
- THRY United States
- Employees
- FHTX N/A
- THRY N/A
- Industry
- FHTX Medicinal Chemicals and Botanical Products
- THRY Industrial Machinery/Components
- Sector
- FHTX Health Care
- THRY Industrials
- Exchange
- FHTX Nasdaq
- THRY Nasdaq
- Market Cap
- FHTX 246.6M
- THRY 256.2M
- IPO Year
- FHTX 2020
- THRY 2020
- Fundamental
- Price
- FHTX $5.21
- THRY $5.67
- Analyst Decision
- FHTX Strong Buy
- THRY Buy
- Analyst Count
- FHTX 6
- THRY 4
- Target Price
- FHTX $11.83
- THRY $14.00
- AVG Volume (30 Days)
- FHTX 270.9K
- THRY 1.2M
- Earning Date
- FHTX 11-05-2025
- THRY 10-30-2025
- Dividend Yield
- FHTX N/A
- THRY N/A
- EPS Growth
- FHTX N/A
- THRY N/A
- EPS
- FHTX N/A
- THRY 0.40
- Revenue
- FHTX $24,518,000.00
- THRY $779,992,000.00
- Revenue This Year
- FHTX $42.43
- THRY N/A
- Revenue Next Year
- FHTX $14.77
- THRY N/A
- P/E Ratio
- FHTX N/A
- THRY $14.41
- Revenue Growth
- FHTX N/A
- THRY N/A
- 52 Week Low
- FHTX $2.95
- THRY $5.61
- 52 Week High
- FHTX $8.45
- THRY $20.92
- Technical
- Relative Strength Index (RSI)
- FHTX 63.51
- THRY 19.42
- Support Level
- FHTX $4.63
- THRY $6.21
- Resistance Level
- FHTX $5.69
- THRY $6.65
- Average True Range (ATR)
- FHTX 0.40
- THRY 0.38
- MACD
- FHTX 0.12
- THRY -0.09
- Stochastic Oscillator
- FHTX 74.95
- THRY 1.66
About FHTX Foghorn Therapeutics Inc.
Foghorn Therapeutics Inc is engaged in the discovery and development of a new class of medicines targeting genetically determined dependencies within the chromatin regulatory system. Its proprietary Gene Traffic Control platform gives an integrated, mechanistic understanding of how the various components of the chromatin regulatory system interact, allowing it to identify, validate, and potentially drug targets within the system. The company is developing FHD-286, a selective, allosteric ATPase inhibitor, and FHD-609, a protein degrader, to treat hematologic cancers and solid tumors.
About THRY Thryv Holdings Inc.
Thryv Holdings Inc is dedicated to supporting local, independent service-based businesses and emerging franchises by providing a cloud-based software platform, and marketing solutions to entrepreneurs. Its company is built upon a rich legacy in the marketing and advertising industry. The group are provider of SaaS all-in-one small business management software in addition to providing print and digital marketing solutions to SMBs. Its solutions enable SMB clients to attract and generate new business leads, manage their customer relationships efficiently with artificial intelligence (AI) tools and automation, and run their day-to-day operations to save time, compete and win in today's SMB environment. The group has two business segments; Thryv SaaS and Thryv Marketing Services.